Belinostat

Template:Infobox drug/title

Clinical data
Trade names	Beleodaq
Synonyms	PXD101
AHFS/Drugs.com	Template:Drugs.com
[[Regulation of therapeutic goods |Template:Engvar data]]	Template:Infobox drug/licence
Pregnancy category	Template:Infobox drug/pregnancy category
Routes of administration	Intravenous (IV)
ATC code	Template:Infobox drug/formatATC Template:Infobox drug/formatATC
Legal status
Legal status	Template:Infobox drug/legal status
Pharmacokinetic data
Bioavailability	100% (IV)
Protein binding	92.9–95.8%
Metabolism	UGT1A1
Excretion	Urine
Identifiers
Template:Collapsible list
CAS Number	Template:Infobox drug/formatCASnumber Template:Infobox drug/formatCASnumber
PubChem CID	Template:Infobox drug/formatPubChemCID Template:Infobox drug/formatPubChemCID
PubChem SID	Template:Infobox drug/formatPubChemSID Template:Infobox drug/formatPubChemSID
IUPHAR/BPS	Template:Infobox drug/formatIUPHARBPS Template:Infobox drug/formatIUPHARBPS
DrugBank	Template:Infobox drug/formatDrugBank Template:Infobox drug/formatDrugBank
ChemSpider	Template:Infobox drug/formatChemSpider Template:Infobox drug/formatChemSpider
UNII	Template:Infobox drug/formatUNII Template:Infobox drug/formatUNII
KEGG	Template:Infobox drug/formatKEGG Template:Infobox drug/formatKEGG
ChEBI	Template:Infobox drug/formatChEBI Template:Infobox drug/formatChEBI
ChEMBL	Template:Infobox drug/formatChEMBL Template:Infobox drug/formatChEMBL
NIAID ChemDB	Template:Infobox drug/formatChemDBNIAID Template:Infobox drug/formatChemDBNIAID
PDB ligand	Template:Infobox drug/formatPDBligand Template:Infobox drug/formatPDBligand
E number	{{#property:P628}}
CompTox Dashboard (EPA)	Template:Infobox drug/formatCompTox Template:Infobox drug/formatCompTox
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	Template:Infobox drug/chemical formula
Molar mass	Template:Chem molar mass
3D model (JSmol)	Template:Infobox drug/formatJmol Template:Infobox drug/formatJmol
Template:Collapsible list
Template:Collapsible list

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.

It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.

In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer. Final results in late 2009 of a phase II trial for T-cell lymphoma were encouraging. Belinostat has been granted orphan drug and fast track designation by the FDA, and was approved in the US for the use against peripheral T-cell lymphoma on 3 July 2014. It is not approved in Europe as of August 2014.

The approved pharmaceutical formulation is given intravenously. Belinostat is primarily metabolized by UGT1A1; the initial dose should be reduced if the recipient is known to be homozygous for the UGT1A1*28 allele.